尽管乳腺癌的治疗取得了显著进步，但三阴性乳腺癌因其对现有激素和靶向疗法的抵抗性，预后仍然较差。基因表达谱分析已使我们能够将乳腺癌分为五个亚型，这些亚型对于预测未来治疗结果可能具有价值。然而，对三阴性乳腺癌生物学的有限理解阻碍了新疗法的开发。识别更多的分子预测标志物并进行前瞻性验证将有助于更好地理解和设计针对这种乳腺癌的最佳治疗方案。
摘要：
We have made remarkable advances in treatment of breast cancer with combination chemotherapies, hormonal therapies, and modern targeted therapies. Triple negative breast cancers carry a poor prognosis, however, and they are insensitive to most available hormonal or targeted therapeutic agents thus far developed. A better understanding of pathophysiology, natural history, and currently available treatment options is necessary to improve outcomes of patients with triple negative breast cancer. Gene expression profiling has allowed us to classify breast cancers into five subtypes based upon distinctive gene expression signatures. This subtyping is prognostic, and the recent literatures suggest that these 'molecular portraits' may be used to predict treatment outcomes in the future. As we prepare for an era of targeted and individualized medicine, limited understanding of triple negative breast cancer biology presents a challenge in developing novel therapies. Identification of more molecular predictive signatures and their prospective validation will enable us to characterize triple negative breast cancers better and design optimal treatment modalities.
展开
扫一扫
6992
被折叠的 条评论
为什么被折叠?
到【灌水乐园】发言
